S&P 500   5,090.98 (+0.04%)
DOW   39,207.39 (+0.19%)
QQQ   436.76 (+0.00%)
AAPL   181.38 (-0.62%)
MSFT   408.87 (-0.36%)
META   482.10 (-0.40%)
GOOGL   140.18 (-2.63%)
AMZN   174.70 (-0.17%)
TSLA   196.40 (+2.31%)
NVDA   790.64 (+0.31%)
NIO   5.72 (+5.93%)
AMD   175.44 (-0.61%)
BABA   76.22 (+0.34%)
T   16.77 (-0.18%)
F   12.26 (+0.99%)
MU   89.81 (+4.43%)
CGC   3.50 (+4.17%)
GE   154.56 (+0.80%)
DIS   108.48 (+0.69%)
AMC   4.53 (+2.03%)
PFE   27.37 (-1.40%)
PYPL   59.22 (+0.10%)
XOM   104.58 (+0.71%)
S&P 500   5,090.98 (+0.04%)
DOW   39,207.39 (+0.19%)
QQQ   436.76 (+0.00%)
AAPL   181.38 (-0.62%)
MSFT   408.87 (-0.36%)
META   482.10 (-0.40%)
GOOGL   140.18 (-2.63%)
AMZN   174.70 (-0.17%)
TSLA   196.40 (+2.31%)
NVDA   790.64 (+0.31%)
NIO   5.72 (+5.93%)
AMD   175.44 (-0.61%)
BABA   76.22 (+0.34%)
T   16.77 (-0.18%)
F   12.26 (+0.99%)
MU   89.81 (+4.43%)
CGC   3.50 (+4.17%)
GE   154.56 (+0.80%)
DIS   108.48 (+0.69%)
AMC   4.53 (+2.03%)
PFE   27.37 (-1.40%)
PYPL   59.22 (+0.10%)
XOM   104.58 (+0.71%)
S&P 500   5,090.98 (+0.04%)
DOW   39,207.39 (+0.19%)
QQQ   436.76 (+0.00%)
AAPL   181.38 (-0.62%)
MSFT   408.87 (-0.36%)
META   482.10 (-0.40%)
GOOGL   140.18 (-2.63%)
AMZN   174.70 (-0.17%)
TSLA   196.40 (+2.31%)
NVDA   790.64 (+0.31%)
NIO   5.72 (+5.93%)
AMD   175.44 (-0.61%)
BABA   76.22 (+0.34%)
T   16.77 (-0.18%)
F   12.26 (+0.99%)
MU   89.81 (+4.43%)
CGC   3.50 (+4.17%)
GE   154.56 (+0.80%)
DIS   108.48 (+0.69%)
AMC   4.53 (+2.03%)
PFE   27.37 (-1.40%)
PYPL   59.22 (+0.10%)
XOM   104.58 (+0.71%)
S&P 500   5,090.98 (+0.04%)
DOW   39,207.39 (+0.19%)
QQQ   436.76 (+0.00%)
AAPL   181.38 (-0.62%)
MSFT   408.87 (-0.36%)
META   482.10 (-0.40%)
GOOGL   140.18 (-2.63%)
AMZN   174.70 (-0.17%)
TSLA   196.40 (+2.31%)
NVDA   790.64 (+0.31%)
NIO   5.72 (+5.93%)
AMD   175.44 (-0.61%)
BABA   76.22 (+0.34%)
T   16.77 (-0.18%)
F   12.26 (+0.99%)
MU   89.81 (+4.43%)
CGC   3.50 (+4.17%)
GE   154.56 (+0.80%)
DIS   108.48 (+0.69%)
AMC   4.53 (+2.03%)
PFE   27.37 (-1.40%)
PYPL   59.22 (+0.10%)
XOM   104.58 (+0.71%)
NASDAQ:LMAT

LeMaitre Vascular (LMAT) Stock Price, News & Analysis

$61.89
-0.30 (-0.48%)
(As of 09:56 AM ET)
Today's Range
$61.69
$62.88
50-Day Range
$54.00
$62.55
52-Week Range
$44.27
$68.67
Volume
4,407 shs
Average Volume
89,203 shs
Market Capitalization
$1.38 billion
P/E Ratio
51.15
Dividend Yield
0.90%
Price Target
$67.60

LeMaitre Vascular MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
8.7% Upside
$67.60 Price Target
Short Interest
Healthy
4.63% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
N/A
News Sentiment
0.77mentions of LeMaitre Vascular in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$2.57 M Sold Last Quarter
Proj. Earnings Growth
13.53%
From $1.33 to $1.51 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.74 out of 5 stars

Medical Sector

249th out of 935 stocks

Surgical & Medical Instruments Industry

31st out of 93 stocks


LMAT stock logo

About LeMaitre Vascular Stock (NASDAQ:LMAT)

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers restoreflow allografts; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access in patients with or without a previously-failed synthetic graft; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

LMAT Stock Price History

LMAT Stock News Headlines

MDT vs. LMAT: Which Stock Should Value Investors Buy Now?
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE!
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets…FOR FREE!
LMAT Jun 2024 70.000 call
LMAT Mar 2024 50.000 call
Billionaires Are Now FLOODING Into Gold
Ray Dalio, John Paulson, and many others all recommend you own gold right now. But did you know there's another huge investor (worth more than all the world's billionaires COMBINED) buying gold by the ton? That's why the best move to make right now could be this little-known gold investment (which you can get started with for just $5).
LeMaitre Vascular Inc LMAT
Stifel Nicolaus Reaffirms Their Hold Rating on Lemaitre Vascular (LMAT)
A First Look At LeMaitre Vascular
Q3 2023 LeMaitre Vascular Inc Earnings Call
LeMaitre Q3 2023 Financial Results
See More Headlines
Receive LMAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LeMaitre Vascular and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Ex-Dividend for 11/30 Dividend
11/15/2023
Dividend Payable
11/30/2023
Today
2/25/2024
Next Earnings (Confirmed)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:LMAT
Employees
591
Year Founded
1983

Price Target and Rating

Average Stock Price Target
$67.60
High Stock Price Target
$75.00
Low Stock Price Target
$60.00
Potential Upside/Downside
+8.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$20.64 million
Pretax Margin
19.38%

Debt

Sales & Book Value

Annual Sales
$185.56 million
Cash Flow
$1.50 per share
Book Value
$12.19 per share

Miscellaneous

Free Float
19,502,000
Market Cap
$1.38 billion
Optionable
Optionable
Beta
0.86

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report














LMAT Stock Analysis - Frequently Asked Questions

Should I buy or sell LeMaitre Vascular stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LMAT shares.
View LMAT analyst ratings
or view top-rated stocks.

What is LeMaitre Vascular's stock price target for 2024?

7 brokerages have issued 1-year price targets for LeMaitre Vascular's stock. Their LMAT share price targets range from $60.00 to $75.00. On average, they anticipate the company's share price to reach $67.60 in the next twelve months. This suggests a possible upside of 8.7% from the stock's current price.
View analysts price targets for LMAT
or view top-rated stocks among Wall Street analysts.

How have LMAT shares performed in 2024?

LeMaitre Vascular's stock was trading at $56.76 at the beginning of the year. Since then, LMAT stock has increased by 9.6% and is now trading at $62.19.
View the best growth stocks for 2024 here
.

When is LeMaitre Vascular's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our LMAT earnings forecast
.

How can I listen to LeMaitre Vascular's earnings call?

LeMaitre Vascular will be holding an earnings conference call on Tuesday, February 27th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were LeMaitre Vascular's earnings last quarter?

LeMaitre Vascular, Inc. (NASDAQ:LMAT) released its earnings results on Wednesday, November, 1st. The medical instruments supplier reported $0.33 earnings per share for the quarter, topping analysts' consensus estimates of $0.31 by $0.02. The medical instruments supplier had revenue of $47.40 million for the quarter, compared to the consensus estimate of $47.58 million. LeMaitre Vascular had a trailing twelve-month return on equity of 9.83% and a net margin of 14.69%. LeMaitre Vascular's revenue was up 21.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.25 EPS.

How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular?

LeMaitre Vascular announced a quarterly dividend on Tuesday, October 24th. Shareholders of record on Thursday, November 16th will be paid a dividend of $0.14 per share on Thursday, November 30th. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date of this dividend is Wednesday, November 15th.
Read our dividend analysis for LMAT
.

Is LeMaitre Vascular a good dividend stock?

LeMaitre Vascular (NASDAQ:LMAT) pays an annual dividend of $0.56 per share and currently has a dividend yield of 0.90%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 46.28%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LMAT will have a dividend payout ratio of 37.09% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LMAT.

What ETFs hold LeMaitre Vascular's stock?

ETFs with the largest weight of LeMaitre Vascular (NASDAQ:LMAT) stock in their portfolio include Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), Invesco S&P SmallCap Health Care ETF (PSCH) and iShares Micro-Cap ETF (IWC).iShares U.S. Medical Devices ETF (IHI).

What is George W. LeMaitre's approval rating as LeMaitre Vascular's CEO?

13 employees have rated LeMaitre Vascular Chief Executive Officer George W. LeMaitre on Glassdoor.com. George W. LeMaitre has an approval rating of 33% among the company's employees. This puts George W. LeMaitre in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of LeMaitre Vascular own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LeMaitre Vascular investors own include AbbVie (ABBV), Sociedad Química y Minera de Chile (SQM), Gilead Sciences (GILD), Aurora Cannabis (ACBFF), NVIDIA (NVDA), Adobe (ADBE), Boeing (BA) and Salesforce (CRM).

Who are LeMaitre Vascular's major shareholders?

LeMaitre Vascular's stock is owned by a number of retail and institutional investors. Top institutional investors include Conestoga Capital Advisors LLC (8.66%), Vanguard Group Inc. (6.96%), Copeland Capital Management LLC (5.66%), Ranger Investment Management L.P. (4.10%), Geneva Capital Management LLC (4.06%) and Dimensional Fund Advisors LP (3.01%). Insiders that own company stock include Bridget A Ross, David B Roberts, George W Lemaitre, George W Lemaitre, John A Roush, Joseph P Pellegrino Jr, Lawrence J Jasinski and Trent G Kamke.
View institutional ownership trends
.

How do I buy shares of LeMaitre Vascular?

Shares of LMAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does LeMaitre Vascular have any subsidiaries?
The following companies are subsidiares of LeMaitre Vascular: Artegraft, Bio Nova Holdings Pty Ltd, Bio Nova International Pty Ltd, Biomateriali, CardioCel, Clinical Instruments, Credent, Endomed, Ideas for Medicine, Inavein, LeMaitre Acquisition LLC, LeMaitre Cardial SAS, LeMaitre Medical Technology (Shanghai) Co., LeMaitre Vascular, LeMaitre Vascular AS, LeMaitre Vascular GK, LeMaitre Vascular GmbH, LeMaitre Vascular Pty Ltd, LeMaitre Vascular S.r.l., LeMaitre Vascular SAS, LeMaitre Vascular Singapore Pte Ltd, LeMaitre Vascular Spain, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LifeSpan, PeriVu, ProCol, Restore Flow Allografts, RestoreFlow, Syntel and Python, TRIVEX, Tru-Incise (Eze-Sit) OUS, Tru-Incise (Eze-Sit) US, UnBalloon, VCS Clip, VascuCel, Vascular Architects, Vascular Innovations, Vascutech Acquisition LLC, Vermed, Whittaker Screen Printing, XenoSure, and Xenotis Pty Ltd.
Read More
This page (NASDAQ:LMAT) was last updated on 2/26/2024 by MarketBeat.com Staff